SCHEMBL6078583

SCHEMBL6078583

CCC(C)c1cc(C=O)c2nc(C)c(C)c(OCc3ccccc3)c2c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
MAPT P10636 1/20 0.35
CCNB2 O95067 2/20 0.34
CDK1 P06493 2/20 0.34
CDK4 P11802 2/20 0.34
CCNB1 P14635 2/20 0.34
CCND1 P24385 2/20 0.34
CCNB3 Q8WWL7 2/20 0.34
TSHR P16473 1/20 0.34
ERN1 O75460 3/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
GLRA1 P23415 1/20 0.33
HSP90AA1 P07900 1/20 0.33
STAT3 P40763 1/20 0.33
HTT P42858 1/20 0.33
BCHE P06276 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6077441 0.84 TDP1 (0.36) SMN1; SMN2L3MBTL1MAPTTSHRMEN1
SCHEMBL6078590 0.80 L3MBTL1 (0.38) SMN1; SMN2NPC1RAB9AL3MBTL1MAPT
SCHEMBL6076666 0.76 ERN1 (0.38) ERN1
SCHEMBL6077263 0.69 TSHR (0.36) SMN1; SMN2L3MBTL1MAPTTSHRMEN1
SCHEMBL6076329 0.69 SMN1; SMN2 (0.40) SMN1; SMN2L3MBTL1MAPTTSHRMEN1
SCHEMBL3103639 0.68 L3MBTL1 (0.50) SMN1; SMN2L3MBTL1MAPTTSHRMEN1
SCHEMBL4049346 0.66 CCNB2 (0.43) SMN1; SMN2L3MBTL1MAPTCCNB2CDK1
SCHEMBL6077445 0.66 THRA (0.42) SMN1; SMN2L3MBTL1MAPTTSHRSTAT3
SCHEMBL3106501 0.65 L3MBTL1 (0.47) SMN1; SMN2NPC1RAB9AL3MBTL1MAPT
SCHEMBL13096569 0.65 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9AL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067668-B2 4-quinolinol derivatives and fungicides containing the same as an active ingredient used for agriculture and horticulture MEIJI SEIKA KAISHA, LTD. (JP) 2006-06-27 US disclosed
EP-0990648-B1 4-QUINOLINOL DERIVATIVES AND AGROHORTICULTURAL BACTERICIDES CONTAINING THE SAME AS ACTIVE INGREDIENT MEIJI SEIKA KAISHA (JP) 2005-11-02 EP disclosed
US-20040152728-A1 4-Quinolinol derivatives and fungicides containing the same as an active ingredient used for agriculture and horticulture MEIJI SEIKA KAISHA, LTD. (JP) 2004-08-05 US disclosed
US-6680282-B2 FUNGICIDE HAVING AN EXCELLENT CONTROL EFFECT; 4-QUINOLINOL DERIVATIVES HAVING SPECIFIC SUBSTITUENT AT 1,2 AND ATLEAST ONE SUBSTITUENT AT 5,6,7,8 POSITION MEIJI SEIKA KAISHA, LTD. (JP) 2004-01-20 US disclosed
US-20030119863-A1 4-Quinolinol derivatives and agrohorticultural bactericides containing the same as active ingredient MEIJI SEIKA PHARMA CO., LTD. (JP) 2003-06-26 US disclosed
EP-0990648-A1 4-QUINOLINOL DERIVATIVES AND AGROHORTICULTURAL BACTERICIDES CONTAINING THE SAME AS ACTIVE INGREDIENT Meiji Seika Kaisha, Ltd. (JP) 2000-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152728-A1 4-Quinolinol derivatives and fungicides containing the same as an active ingredient used for agriculture and horticulture CYP51A1, CYP4X1, CYP4Z1 SMN1; SMN2 4492/4885NPC1 4124/4885RAB9A 2467/4885
US-20030119863-A1 4-Quinolinol derivatives and agrohorticultural bactericides containing the same as active ingredient CYP51A1, DDT, PGLS SMN1; SMN2 4579/4885NPC1 3837/4885RAB9A 785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.